ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022
Nanoneedles Induce Targeted siRNA Silencing of p16 in the Human Corneal Endothelium.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Poking Pluripotency: Nanoinjection Into Human iPSCs.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Caveolar Endocytosis Governs Nanoneedle Transfection.ACS nano · 2026Article
- Current Landscape and Future Prospects of Corneal Regenerative Medicine.Ophthalmology and therapy · 2026Review
- Article
- Bioactive Silk Sericin/Bioceramic Nerve Guidance Conduit for Effective Repair of Long-Gap Transected Peripheral Nerve Injury through Regulating Schwann Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Nanoneedle-Based Transdermal Gene Delivery: A Minimally Invasive Strategy for Gene Therapy.International journal of molecular sciences · 2025Review
- Nanoneedle-Based Electroporation for Efficient Manufacturing of Human Primary Chimeric Antigen Receptor Regulatory T-Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Porous Silicon Nanoneedles Efficiently Deliver Adenine Base Editor to Correct a Recurrent Pathogenic COL7A1 Variant in Recessive Dystrophic Epidermolysis Bullosa.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Review
- Spatially-Resolved Organoid Transfection by Porous Silicon-Mediated Optoporation.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- A cellular disease model toward gene therapy ofMolecular therapy. Methods & clinical development · 2024Article
- Nanoinjection: A Platform for Innovation in Ex Vivo Cell Engineering.Accounts of chemical research · 2024Article
- Influencing Endothelial Cells' Roles in Inflammation and Wound Healing Through Nucleic Acid Delivery.Tissue engineering. Part A · 2024Review
- CRISPR/Cas-Assisted Nanoneedle Sensor for Adenosine Triphosphate Detection in Living Cells.ACS applied materials & interfaces · 2023Article
- Nanoneedles Induce Targeted siRNA Silencing of p16 in the Human Corneal Endothelium.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
Abstract
Nanoneedles can target nucleic acid transfection to primary cells at tissue interfaces with high efficiency and minimal perturbation. The corneal endothelium is an ideal target for nanoneedle-mediated RNA interference therapy aimed at enhancing its proliferative capacity, necessary for tissue regeneration. This work develops a strategy for siRNA nanoninjection to the human corneal endothelium. Nanoneedles can deliver p16-targeting siRNA to primary human corneal endothelial cells in vitro without toxicity. The nanoinjection of siRNA induces p16 silencing and increases cell proliferation, as monitored by ki67 expression. Furthermore, siRNA nanoinjection targeting the human corneal endothelium is nontoxic ex vivo, and silences p16 in transfected cells. These data indicate that nanoinjection can support targeted RNA interference therapy for the treatment of endothelial corneal dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.